Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies continuous intraventricular methotrexate in treating
patients with leptomeningeal disease. Drugs used in chemotherapy, such as methotrexate, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving drugs directly into the ventricles may be an effective
treatment for patients with leptomeningeal disease